Carolina Sanz

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 107 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas

Gustavo Tapia, Raquel Larrosa López, Ana M Muñoz‐Mármol et al. · Histopathology · 2011 · 71 citations

Medicine, Molecular Biology, Oncology +17

Structure of the periplasmic domain of Pseudomonas aeruginosa TolA: evidence for an evolutionary relationship with the TonB transporter protein

Michael J. Witty, Carolina Sanz, Amish Shah et al. · The EMBO Journal · 2002 · 65 citations · Full text

Life Sciences, Microbiology, Molecular Biology +16

<i><scp>MYC</scp></i> status determination in aggressive <scp>B</scp>‐cell lymphoma: the impact of <scp>FISH</scp> probe selection

Ana M Muñoz‐Mármol, Carolina Sanz, Gustavo Tapia et al. · Histopathology · 2013 · 59 citations

Medicine, Oncology, Pathology +16

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

Carmen Balañá, Juan Manuel Sepúlveda-Sánchez, Miguel Gil‐Gil et al. · Journal of Neuro-Oncology · 2016 · 55 citations

Medicine, Oncology, Pharmacology +17